Ivosidenib Holds Greatest Benefit for Older Patients With IDH1-Mutant AML

Brittany Lovely
Published: Tuesday, Apr 16, 2019
Dr Courtney D. DiNardo

Courtney D. DiNardo, MD
Ivosidenib (Tibsovo) is changing the treatment landscape for adult patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation. The FDA approved ivosidenib in July 2018 to treat this patient population.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication